CN113272324A - 使用抗cgrp或抗cgrp-r抗体治疗药物过度使用性头痛 - Google Patents

使用抗cgrp或抗cgrp-r抗体治疗药物过度使用性头痛 Download PDF

Info

Publication number
CN113272324A
CN113272324A CN202080007409.XA CN202080007409A CN113272324A CN 113272324 A CN113272324 A CN 113272324A CN 202080007409 A CN202080007409 A CN 202080007409A CN 113272324 A CN113272324 A CN 113272324A
Authority
CN
China
Prior art keywords
seq
cgrp
headache
cgrp antibody
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080007409.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·K·卡迪
J·T·L·史密斯
J·希尔曼
B·舍夫勒
L·梅塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to CN202411285298.5A priority Critical patent/CN119303074A/zh
Publication of CN113272324A publication Critical patent/CN113272324A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080007409.XA 2019-01-08 2020-01-08 使用抗cgrp或抗cgrp-r抗体治疗药物过度使用性头痛 Pending CN113272324A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411285298.5A CN119303074A (zh) 2019-01-08 2020-01-08 使用抗cgrp或抗cgrp-r抗体治疗药物过度使用性头痛

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962789828P 2019-01-08 2019-01-08
US62/789,828 2019-01-08
US201962840967P 2019-04-30 2019-04-30
US62/840,967 2019-04-30
US201962841585P 2019-05-01 2019-05-01
US62/841,585 2019-05-01
US201962872983P 2019-07-11 2019-07-11
US62/872,983 2019-07-11
PCT/US2020/012790 WO2020146535A1 (en) 2019-01-08 2020-01-08 Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411285298.5A Division CN119303074A (zh) 2019-01-08 2020-01-08 使用抗cgrp或抗cgrp-r抗体治疗药物过度使用性头痛

Publications (1)

Publication Number Publication Date
CN113272324A true CN113272324A (zh) 2021-08-17

Family

ID=71404208

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080007409.XA Pending CN113272324A (zh) 2019-01-08 2020-01-08 使用抗cgrp或抗cgrp-r抗体治疗药物过度使用性头痛
CN202411285298.5A Pending CN119303074A (zh) 2019-01-08 2020-01-08 使用抗cgrp或抗cgrp-r抗体治疗药物过度使用性头痛

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411285298.5A Pending CN119303074A (zh) 2019-01-08 2020-01-08 使用抗cgrp或抗cgrp-r抗体治疗药物过度使用性头痛

Country Status (24)

Country Link
US (2) US20200216525A1 (enExample)
EP (1) EP3908607A4 (enExample)
JP (2) JP2022516957A (enExample)
KR (1) KR20210114002A (enExample)
CN (2) CN113272324A (enExample)
AU (1) AU2020207299A1 (enExample)
BR (1) BR112020018044A2 (enExample)
CA (1) CA3123292A1 (enExample)
CL (1) CL2021001813A1 (enExample)
CO (1) CO2021008665A2 (enExample)
DO (1) DOP2021000145A (enExample)
EC (1) ECSP21052193A (enExample)
GE (2) GEAP202515689A (enExample)
IL (1) IL284677A (enExample)
JO (1) JOP20210166A1 (enExample)
MA (1) MA54709A (enExample)
MX (1) MX2021008268A (enExample)
NI (1) NI202100063A (enExample)
PE (1) PE20211708A1 (enExample)
PH (1) PH12021551494A1 (enExample)
SG (1) SG11202106878XA (enExample)
TW (1) TW202030205A (enExample)
UA (1) UA129265C2 (enExample)
WO (1) WO2020146535A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024032750A1 (zh) * 2022-08-11 2024-02-15 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2709662T3 (da) 2011-05-20 2019-11-04 Alderbio Holdings Llc Anvendelse af anti-cgrp- eller anti-cgrp-r-antistoffer eller antistoffragmenter til behandling eller forebyggelse af kroniske og akutte former for diarré
SMT201900293T1 (it) 2011-05-20 2019-07-11 Alderbio Holdings Llc Composizioni comprendenti anticorpi anti-cgrp e loro utilizzo
EP3508501B1 (en) 2011-05-20 2024-11-06 H. Lundbeck A/S Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
EP3908606A4 (en) 2019-01-08 2022-11-23 H. Lundbeck A/S ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE WITH ANTI-CGRP ANTIBODIES
BR102020007149A8 (pt) 2020-04-06 2023-09-26 H Lundbeck As Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
KR20240049275A (ko) * 2021-08-27 2024-04-16 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용한 군발성 두통의 치료
CN118476508A (zh) * 2024-06-27 2024-08-13 中国人民解放军总医院第一医学中心 一种基于疾病发生特点的药物过度使用性头痛动物模型的构建方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103585449A (zh) * 2013-10-23 2014-02-19 青岛华仁技术孵化器有限公司 用于治疗偏头痛的中药组合物
CN103702685A (zh) * 2011-05-20 2014-04-02 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途
US20180127490A1 (en) * 2016-09-23 2018-05-10 Teva Pharmaceuticals International Gmbh Treating refractory migraine
CN108137677A (zh) * 2015-04-16 2018-06-08 奥尔德生物制药公司 抗pacap抗体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
SMT201900293T1 (it) * 2011-05-20 2019-07-11 Alderbio Holdings Llc Composizioni comprendenti anticorpi anti-cgrp e loro utilizzo
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3908606A4 (en) * 2019-01-08 2022-11-23 H. Lundbeck A/S ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE WITH ANTI-CGRP ANTIBODIES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702685A (zh) * 2011-05-20 2014-04-02 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途
CN107827982A (zh) * 2011-05-20 2018-03-23 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
CN108014334A (zh) * 2011-05-20 2018-05-11 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
CN103585449A (zh) * 2013-10-23 2014-02-19 青岛华仁技术孵化器有限公司 用于治疗偏头痛的中药组合物
CN108137677A (zh) * 2015-04-16 2018-06-08 奥尔德生物制药公司 抗pacap抗体及其用途
US20180127490A1 (en) * 2016-09-23 2018-05-10 Teva Pharmaceuticals International Gmbh Treating refractory migraine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAROLINE MACHADO KOPRUSZINSKI: "Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents", INTERNATIONAL HEADACHE SOCIETY, 19 May 2016 (2016-05-19), pages 560 *
张金英: "曲唑酮联合托吡酯治疗药物过度使用性头痛的疗效", 中国疼痛医学杂志, 15 July 2017 (2017-07-15), pages 507 - 510 *
赵颖奇;: "偏头痛患者药物过度使用性头痛相关因素及临床特点", 中国实用神经疾病杂志, no. 22, 25 November 2014 (2014-11-25) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024032750A1 (zh) * 2022-08-11 2024-02-15 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途

Also Published As

Publication number Publication date
CA3123292A1 (en) 2020-07-16
CL2021001813A1 (es) 2021-12-24
JOP20210166A1 (ar) 2023-01-30
ECSP21052193A (es) 2021-08-31
US20200216525A1 (en) 2020-07-09
TW202030205A (zh) 2020-08-16
WO2020146535A1 (en) 2020-07-16
CO2021008665A2 (es) 2021-07-19
CN119303074A (zh) 2025-01-14
PH12021551494A1 (en) 2023-05-08
MA54709A (fr) 2022-04-13
GEP20257804B (en) 2025-10-10
JP2025032102A (ja) 2025-03-11
UA129265C2 (uk) 2025-03-05
US20240343784A1 (en) 2024-10-17
IL284677A (en) 2021-08-31
GEAP202515689A (en) 2025-04-25
SG11202106878XA (en) 2021-07-29
AU2020207299A1 (en) 2021-08-26
PE20211708A1 (es) 2021-09-01
EP3908607A1 (en) 2021-11-17
BR112020018044A2 (pt) 2021-08-10
NI202100063A (es) 2021-12-01
DOP2021000145A (es) 2021-10-31
KR20210114002A (ko) 2021-09-17
MX2021008268A (es) 2021-08-05
EP3908607A4 (en) 2022-10-05
JP2022516957A (ja) 2022-03-03

Similar Documents

Publication Publication Date Title
CN113227140A (zh) 使用抗cgrp抗体急性治疗和快速治疗头痛
CN113272324A (zh) 使用抗cgrp或抗cgrp-r抗体治疗药物过度使用性头痛
AU2019226231B2 (en) Anti-CGRP compositions and use thereof
KR102098546B1 (ko) 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
CN108359008B (zh) 抗cgrp或抗cgrp-r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
KR102363008B1 (ko) 표적화된 TGFβ 억제
KR102137291B1 (ko) 항-pcsk9 항체 및 그의 용도
KR102791781B1 (ko) 항-cxcr5 항체 및 그의 조성물 및 용도
CN112210000A (zh) 突变体白介素-2多肽
CN111448323B (zh) 精确制导的多功能治疗抗体
KR102476907B1 (ko) 항-ｃｇｒｐ 항체를 사용하는 글루코오스 대사의 조절
CN113811326A (zh) 使用抗cgrp抗体治疗头痛
RU2826186C2 (ru) Лечение головной боли при избыточном применении лекарственных препаратов антителами к cgrp или cgrp-r
RU2852374C2 (ru) Неотложное лечение и быстрое лечение головной боли с использованием антител к cgrp
KR20210124867A (ko) 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
HK40044689A (en) Mutant interleukin-2 polypeptides
HK1259303B (en) Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
HK40037035A (en) Anti-cxcr5 antibodies and compositions and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210817